BCIQ Profiles

Company Profile Report
0518 Outpace ECP
BioCentury & Getty Images

Emerging Company Profile

Lyell spinout Outpace leverages de novo proteins to control cell and gene therapies

By choosing to be an early development partner instead of a pipeline company, Outpace thinks it can transform cell and gene therapy across the board

By choosing to be an early development partner instead of a pipeline company, Outpace thinks it can transform cell and gene therapy across the board.

May 18, 2021 | 11:00 PM GMT

Outpace is taking cell and gene control technology originally in-licensed by Lyell out of that company’s toolbox and into a broad partnering

Read the full 987 word article

How to gain access

Continue reading with a
two-week free trial.